1-kestose and Dermatitis--Atopic

Oligosaccharides may have beneficial properties of the prevention of atopic dermatitis (AD). Kestose, a fructo-oligosaccharide, stimulates the activity of bifidobacteria.. To assess the clinical effect of kestose on the treatment of AD in infants.. A randomized, double-blind, placebo-controlled trial was carried out using 15 and 14 infants with AD in the kestose group and placebo groups, respectively. One to 2 g kestose and maltose were administered to the subjects in the kestose and placebo groups, respectively, everyday for 12 weeks. Clinical evaluations of AD using Severity Scoring of Atopic Dermatitis (SCORAD) and the enumeration of bifidobacteria in the feces using real-time PCR were performed at Weeks 0, 6, and 12.. The medians of the SCORAD score were significantly lower in the kestose group than in the placebo group on both Week 6 (25.3 vs. 36.4; P=0.004) and Week 12 (19.5 vs. 37.5; P<0.001). No significant correlation was found between the improvement of the SCORAD score and the count of bifidobacteria.. Kestose was found to exert a beneficial effect on the clinical symptoms in infants with AD. The mechanism how does kestose improve the symptoms of AD remains to be elucidated.

Topics: Bifidobacterium; Child, Preschool; Dermatitis, Atopic; Double-Blind Method; Feces; Female; Humans; Infant; Infant, Newborn; Male; Maltose; Sweetening Agents; Time Factors; Trisaccharides

Atopic dermatitis (AD) is recently increasing among populations, but the underlying mechanisms remain controversial. Interactions between the gut microbiota and mucosal immunity are considered to be a crucial etiology. Fructooligosaccharide (FOS), prebiotics have been reported as activators of the gut microbiota.. The aim of this study was to investigate the effects of kestose, the smallest FOS and FOS on atopic dermatitis in mice.. An AD mouse model was developed by (ovalbumin) epidermal sensitization using BALB/c mice. Kestose (1%, 5%, and 10%) or FOS (5%, positive control) was orally administered throughout the study.. In comparison with the values observed for the control AD mice, transepidermal water loss (TEWL), clinical score, and skin inflammation on histopathology were significantly decreased by the oral administration of kestose. Total IgE, thymic stromal lymphopoietin (TSLP) in skin, and IL-4 were also suppressed by this administration. In addition, the population of CD4. These findings suggest that kestose activates the gut immune system to induce the tolerance against allergic skin inflammations in AD.

Topics: Animals; CD4-Positive T-Lymphocytes; Dermatitis, Atopic; Disease Models, Animal; Epidermis; Female; Food Hypersensitivity; Gastrointestinal Microbiome; Humans; Immune Tolerance; Immunity, Mucosal; Intestinal Mucosa; Mice; Mice, Inbred BALB C; Ovalbumin; Trisaccharides